JP2018530574A - 患者の加齢黄斑変性を治療する方法 - Google Patents

患者の加齢黄斑変性を治療する方法 Download PDF

Info

Publication number
JP2018530574A
JP2018530574A JP2018518654A JP2018518654A JP2018530574A JP 2018530574 A JP2018530574 A JP 2018530574A JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018530574 A JP2018530574 A JP 2018530574A
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
cells
eculizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018518654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530574A5 (enExample
Inventor
ワン、イー
ローラー、バーベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018530574A publication Critical patent/JP2018530574A/ja
Publication of JP2018530574A5 publication Critical patent/JP2018530574A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018518654A 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法 Pending JP2018530574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238483P 2015-10-07 2015-10-07
US62/238,483 2015-10-07
PCT/US2016/055794 WO2017062649A1 (en) 2015-10-07 2016-10-06 A method for treating age-related macular degeneration in a patient

Publications (2)

Publication Number Publication Date
JP2018530574A true JP2018530574A (ja) 2018-10-18
JP2018530574A5 JP2018530574A5 (enExample) 2019-11-14

Family

ID=57200105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518654A Pending JP2018530574A (ja) 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法

Country Status (4)

Country Link
US (1) US11203634B2 (enExample)
EP (1) EP3359566A1 (enExample)
JP (1) JP2018530574A (enExample)
WO (1) WO2017062649A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022530068A (ja) * 2019-04-25 2022-06-27 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 治療法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
EP4397306A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
AU2024271004A1 (en) * 2023-05-16 2026-01-15 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2025036488A1 (en) * 2023-08-17 2025-02-20 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500289A (ja) * 1994-05-02 1998-01-13 アレクション・ファーマシューティカル・インク 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2013526861A (ja) * 2010-04-30 2013-06-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500289A (ja) * 1994-05-02 1998-01-13 アレクション・ファーマシューティカル・インク 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2013526861A (ja) * 2010-04-30 2013-06-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXION 2010 ANNUAL REPORT, JPN6020036150, 2011, pages 1 - 11, ISSN: 0004500997 *
BUSCHINI, E. ET AL., CLIN OPHTHALMOL, vol. 9, JPN6020036143, April 2015 (2015-04-01), pages 563 - 74, ISSN: 0004500996 *
NOZAKI, M. ET AL., PROC NATL ACAD SCI U S A, vol. 103, no. 7, JPN6020036152, 2006, pages 2328 - 33, ISSN: 0004352996 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022530068A (ja) * 2019-04-25 2022-06-27 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 治療法
JP7603612B2 (ja) 2019-04-25 2024-12-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 治療法

Also Published As

Publication number Publication date
US11203634B2 (en) 2021-12-21
EP3359566A1 (en) 2018-08-15
WO2017062649A1 (en) 2017-04-13
US20190218278A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
AU2019201826B2 (en) Targeting constructs based on natural antibodies and uses thereof
CN105963694B (zh) 抗-c5a抗体和使用所述抗体的方法
US9815890B2 (en) Antibodies to the C3d fragment of complement component 3
EP1948234B1 (en) Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
KR102277166B1 (ko) Masp-2 의존성 보체 활성화와 관련된 질병의 치료 방법
US11203634B2 (en) Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
TW201542590A (zh) 具有改善的藥物動力學的抗ｃ５抗體
MX2014004449A (es) Tratamiento de enfermedad ocular.
JP2018111728A (ja) 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
CN106687123A (zh) Map44多肽和基于天然抗体的构建体及其用途
KR20230146053A (ko) 보체 c3 항원 결합 단백질
CN116710135A (zh) 用于治疗眼部疾病的方法和试剂
JP2024546183A (ja) 抗ｃ３抗体及びその抗原結合性断片並びに眼科疾患又は眼疾患を処置するためのそれらの使用
TWI923686B (zh) 補體c3抗原結合蛋白
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210507